Neoplasms, Unknown Primary
-
Subject Areas on Research
- A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer.
- Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin.
- Are time or intensity factors important to the definition of metastases of unknown origin?
- Can Occult Invasive Disease in Ductal Carcinoma In Situ Be Predicted Using Computer-extracted Mammographic Features?
- Cancers of unknown primary origin (CUP) are characterized by chromosomal instability (CIN) compared to metastasis of know origin.
- Carcinoids of unknown origin: comparative analysis with foregut, midgut, and hindgut carcinoids.
- Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study.
- Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions.
- Characterizing postoperative physiologic swallow function following transoral robotic surgery for early stage tonsil, base of tongue, and unknown primary human papillomavirus-associated squamous cell carcinoma.
- Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma.
- Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin.
- Detection of primary breast cancer presenting as metastatic carcinoma of unknown primary origin by 111In-pentetreotide scan.
- Diagnostic strategies for unknown primary cancer.
- Fluorodeoxyglucose-positron-emission tomography imaging of head and neck squamous cell cancer.
- Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry.
- Melanomas of Unknown Primary May Have a Distinct Molecular Classification to Explain Differences in Patient Outcomes.
- Metastatic adenocarcinoma to the neck from an unknown primary source.
- Metastatic adenocarcinomas of unknown primary site. Prognostic variables and treatment results.
- Metastatic squamous cell carcinoma with pseudoangiosarcomatous features and aberrant expression of vascular markers.
- Metastatic vs primary malignant neoplasms affecting the umbilicus: clinicopathologic features of 77 tumors.
- Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.
- Multiple endocrine neoplasia type 1 manifesting with chronic and persistent diarrhea.
- NCCN Clinical Practice Guidelines Occult primary.
- NCCN practice guidelines for occult primary tumors. National Comprehensive Cancer Network.
- Occult primary cancer clinical practice guidelines.
- Occult primary, version 3.2014.
- Occult primary.
- Phase II study of cisplatin, 5-fluorouracil and folinic acid in patients with carcinoma of unknown primary origin.
- Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?
- Prognostic risk factors in low stage testicular germ cell tumors: unanswered questions regarding clinically useful prognosticators for extratesticular disease.
- Prognostic stratification in UPC: a role for assessing the value of conventional-dose and high-dose chemotherapy for unknown primary carcinoma.
- Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary.
- Somatic mosaicism caused by monoallelic reversion of a mutation in T cells of a patient with ADA-SCID and the effects of enzyme replacement therapy on the revertant phenotype.
- The biology of unknown primary tumors.
- Unknown primary cancer presenting as an adrenal mass: frequency and implications for diagnostic evaluation of adrenal incidentalomas.
- Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients.
- Unknown primary tumors metastatic to liver.
- Unknown primary tumors.
- p53 gene mutation spectrum in human unknown primary tumors.